The FDA has granted Emergency Use (EUA) approval for Fluidigm Corporation's FLDM AZOVA COVID-19 test collection kit for use with the company's Advanta Dx SARS-CoV-2 RT-PCR Assay on its Biomark HD platform.
- The kit is authorized for at-home self-collection by prescription only for individuals suspected of COVID-19 infection.
- Advanta Dx SARS-CoV-2 RT-PCR assay is an extraction-free saliva-based test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in saliva specimens.
- The assay is only for use under the FDA's Emergency Use Authorization.
- Price Action: FLDM shares are up 2.5% at $4.71 in market trading hours on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in